An Open-Label, Two-Part, Single-Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of MK-3102 in Patients With Impaired Renal Function.

Trial Profile

An Open-Label, Two-Part, Single-Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of MK-3102 in Patients With Impaired Renal Function.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Omarigliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 24 Apr 2012 Actual patients number is 49 as reported by ClinicalTrials.gov.
    • 10 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top